PET-MR-PSA Prostate Cancer Recidive Study

Simultaneous PET/MRI has the potential to improve the detection accuracy in recurrent prostate cancer, since it combines the excellent soft-tissue contrast of MRI with the high molecular sensitivity of PET in a single imaging session. The aim of this study is to evaluate the sensitivity and specificity of simultaneous 18F-Fluciclovine PET/MRI for detection of recurrent prostate cancer.

Study Type: Observational

Study Design: Observational Model: Case-Only

Time Perspective: Prospective

Official Title: 18F-Fluciclovine PET/MRI for Detection of Recurrent Prostate Cancer After Radical Treatment

Estimated Enrollment: 80

Study Start Date: September 2015

Estimated Study Completion Date: December 2027

Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)